- Home
- CYH vs CRMD Comparison
CYH vs CRMD Comparison
Compare CYH & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYH
- CRMD
- Stock Information
- Founded
- CYH 1985
- CRMD 2006
- Country
- CYH United States
- CRMD United States
- Employees
- CYH N/A
- CRMD 82
- Industry
- CYH Hospital/Nursing Management
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- CYH Health Care
- CRMD Health Care
- Exchange
- CYH Nasdaq
- CRMD Nasdaq
- Market Cap
- CYH 410.5M
- CRMD 865.2M
- IPO Year
- CYH 1991
- CRMD 2010
- Fundamental
- Price
- CYH $2.94
- CRMD $11.12
- Analyst Decision
- CYH Hold
- CRMD Strong Buy
- Analyst Count
- CYH 8
- CRMD 8
- Target Price
- CYH $3.57
- CRMD $17.57
- AVG Volume (30 Days)
- CYH 1.5M
- CRMD 4.6M
- Earning Date
- CYH 10-22-2025
- CRMD 10-29-2025
- Dividend Yield
- CYH N/A
- CRMD N/A
- EPS Growth
- CYH N/A
- CRMD N/A
- EPS
- CYH N/A
- CRMD 0.79
- Revenue
- CYH $12,647,000,000.00
- CRMD $121,484,498.00
- Revenue This Year
- CYH N/A
- CRMD $404.81
- Revenue Next Year
- CYH $2.46
- CRMD $56.11
- P/E Ratio
- CYH N/A
- CRMD $14.00
- Revenue Growth
- CYH 0.81
- CRMD 14970.29
- 52 Week Low
- CYH $2.24
- CRMD $5.60
- 52 Week High
- CYH $6.29
- CRMD $17.43
- Technical
- Relative Strength Index (RSI)
- CYH 54.74
- CRMD 34.64
- Support Level
- CYH $2.86
- CRMD $12.73
- Resistance Level
- CYH $3.04
- CRMD $13.83
- Average True Range (ATR)
- CYH 0.12
- CRMD 0.81
- MACD
- CYH 0.02
- CRMD -0.30
- Stochastic Oscillator
- CYH 57.47
- CRMD 0.90
About CYH Community Health Systems Inc.
Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.